Ketogenic diets consumed during radio-chemotherapy have beneficial effects on quality of life and metabolic health in patients with rectal cancer.


Journal

European journal of nutrition
ISSN: 1436-6215
Titre abrégé: Eur J Nutr
Pays: Germany
ID NLM: 100888704

Informations de publication

Date de publication:
Feb 2022
Historique:
received: 07 04 2021
accepted: 08 06 2021
pubmed: 28 6 2021
medline: 27 1 2022
entrez: 27 6 2021
Statut: ppublish

Résumé

Interest in ketogenic diets (KDs) as complementary nutritional treatments for cancer patients is rising, although some skepticism about their safety exists. We, therefore, studied the effects of KDs on quality of life and blood parameters in rectal cancer patients undergoing radio-chemotherapy. EORTC-QLQ30 questionnaire scores and different metabolic and hormonal blood parameters were obtained prior to, in the middle of and at the end of radiotherapy within the KETOCOMP study (ClinicalTrials.gov Identifier: NCT02516501). A total of 18 patients consuming a KD were compared to 23 patients consuming their standard diet (SD). Baseline-end differences were measured using Wilcoxon tests, and repeated measures analysis was performed using linear mixed effects models. Eighty-nine percent of patients on the KD reported subjectively feeling good or very good, but roughly half of them rated the daily routine implementation as difficult. Only the SD group experienced significant declines in physical and role functioning, while the KD group improved in role (p = 0.045), emotional (p = 0.018) and social functioning (p = 0.009).Urinary frequency, buttock pain and fatigue significantly increased in the SD group, but to a much lesser extent in the KD group. Several biomarkers of metabolic health (gamma-glutamyl-transpeptidase, triglyceride-glucose index, HDL cholesterol/triglyceride ratio, and free T3) improved in the KD, but not the SD group. Despite being perceived as difficult to implement by ≈50% of patients, KDs are feasible as complementary therapies alongside radio-chemotherapy and associated with subjective well-being. The hypothesis that they exert beneficial effects on quality of life and metabolic health in rectal cancer patients is supported by our data. ClinicalTrials.gov identifier NCT02516501, registered Aug 6th 2015.

Identifiants

pubmed: 34175978
doi: 10.1007/s00394-021-02615-y
pii: 10.1007/s00394-021-02615-y
doi:

Banques de données

ClinicalTrials.gov
['NCT02516501']

Types de publication

Controlled Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

69-84

Informations de copyright

© 2021. Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Miller VJ, Villamena FA, Volek JS (2018) Nutritional ketosis and mitohormesis: potential implications for mitochondrial function and human health. J Nutr Metab 2018:5157645
doi: 10.1155/2018/5157645
Allott EH, Macias E, Sanders S et al (2017) Impact of carbohydrate restriction in the context of obesity on prostate tumor growth in the Hi-Myc transgenic mouse model. Prostate Cancer Prostatic Dis 20:165–171. https://doi.org/10.1038/pcan.2016.73
doi: 10.1038/pcan.2016.73 pubmed: 28244492 pmcid: 5429178
Hao G-W, Chen Y-S, He D-M et al (2015) Growth of human colon cancer cells in nude mice is delayed by ketogenic diet with or without omega-3 fatty acids and medium-chain triglycerides. Asian Pac J Cancer Prev 16:2061–2068
doi: 10.7314/APJCP.2015.16.5.2061
Nakamura K, Tonouchi H, Sasayama A, Ashida K (2018) A ketogenic formula prevents tumor progression and cancer cachexia by attenuating systemic inflammation in colon 26 tumor-bearing mice. Nutrients 10:206. https://doi.org/10.3390/nu10020206
doi: 10.3390/nu10020206 pmcid: 5852782
Stafford P, Abdelwahab MG, Kim DY et al (2010) The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr Metab (Lond) 7:74
doi: 10.1186/1743-7075-7-74
Tisdale MJ, Brennan RA, Fearon KC (1987) Reduction of weight loss and tumour size in a cachexia model by a high fat diet. Br J Cancer 56:39–43. https://doi.org/10.1038/bjc.1987.149
doi: 10.1038/bjc.1987.149 pubmed: 3620317 pmcid: 2001676
Abdelwahab MG, Fenton KE, Preul MC et al (2012) The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. PLoS ONE 7:e36197. https://doi.org/10.1371/journal.pone.0036197
doi: 10.1371/journal.pone.0036197 pubmed: 22563484 pmcid: 3341352
Allen BG, Bhatia SK, Buatti JM et al (2013) Ketogenic diets enhance oxidative stress and radio-chemo-therapy responses in lung cancer xenografts. Clin Cancer Res 19:3905–3913. https://doi.org/10.1158/1078-0432.CCR-12-0287
doi: 10.1158/1078-0432.CCR-12-0287 pubmed: 23743570 pmcid: 3954599
Aminzadeh-Gohari S, Feichtinger RG, Vidali S, et al (2017) A ketogenic diet supplemented with medium-chain triglycerides enhances the anti-tumor and anti-angiogenic efficacy of chemotherapy on neuroblastoma xenografts in a CD1-nu mouse model. Oncotarget 8:64728–64744. https://doi.org/10.18632/oncotarget.20041
Hopkins BD, Pauli C, Du X et al (2018) Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature 560:499–503. https://doi.org/10.1038/s41586-018-0343-4
doi: 10.1038/s41586-018-0343-4 pubmed: 30051890 pmcid: 6197057
Maeyama M, Tanaka K, Nishihara M et al (2021) Metabolic changes and anti-tumor effects of a ketogenic diet combined with anti-angiogenic therapy in a glioblastoma mouse model. Sci Rep 11:79. https://doi.org/10.1038/s41598-020-79465-x
doi: 10.1038/s41598-020-79465-x pubmed: 33420169 pmcid: 7794443
Ferrere G, Tidjani Alou M, Liu P et al (2021) Ketogenic diet and ketone bodies enhance the anticancer effects of PD1 blockade. JCI Insight 6:e145207. https://doi.org/10.1172/jci.insight.145207
doi: 10.1172/jci.insight.145207 pmcid: 7934884
Schmidt M, Pfetzer N, Schwab M et al (2011) Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: A pilot trial. Nutr Metab (Lond) 8:54
doi: 10.1186/1743-7075-8-54
Fine EJ, Segal-isaacson CJ, Feinman RD et al (2012) Targeting insulin inhibition as a metabolic therapy in advanced cancer: a pilot safety and feasibility dietary trial in 10 patients. Nutrition 28:1028–1035. https://doi.org/10.1016/j.nut.2012.05.001
doi: 10.1016/j.nut.2012.05.001 pubmed: 22840388
Rieger J, Bähr O, Maurer GD et al (2014) ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol 44:1843–1852. https://doi.org/10.3892/ijo.2014.2382
doi: 10.3892/ijo.2014.2382 pubmed: 24728273 pmcid: 4063533
Voss M, von Mettenheim N, Harter P et al (2020) ERGO2: a prospective randomized trial of calorie restricted ketogenic diet and fasting in addition to re-irradiation for malignant glioma. Int J Radiat Oncol Biol Phys 108:987–995. https://doi.org/10.1016/j.ijrobp.2020.06.021
doi: 10.1016/j.ijrobp.2020.06.021 pubmed: 32619561
Tan-Shalaby JL, Carrick J, Edinger K et al (2016) Modified Atkins diet in advanced malignancies—final results of a safety and feasibility trial within the veterans affairs Pittsburgh healthcare system. Nutr Metab (Lond) 13:52. https://doi.org/10.1186/s12986-016-0113-y
doi: 10.1186/s12986-016-0113-y
Cohen CW, Fontaine KR, Arend RC et al (2018) A ketogenic diet reduces central obesity and serum insulin in women with ovarian or endometrial cancer. J Nutr 148:1253–1260. https://doi.org/10.1093/jn/nxy119
doi: 10.1093/jn/nxy119 pubmed: 30137481 pmcid: 8496516
Khodabakhshi A, Akbari ME, Mirzaei HR et al (2019) Feasibility, safety, and beneficial effects of MCT-based ketogenic diet for breast cancer treatment: a randomized controlled trial study. Nutr Cancer 72:627–634. https://doi.org/10.1080/01635581.2019.1650942
doi: 10.1080/01635581.2019.1650942 pubmed: 31496287
Hagihara K, Kajimoto K, Osaga S et al (2020) Promising effect of a new ketogenic diet regimen in patients with advanced cancer. Nutrients 12:1473. https://doi.org/10.3390/nu12051473
doi: 10.3390/nu12051473 pmcid: 7284721
Hyde PN, Lustberg MB, Miller VJ et al (2017) Pleiotropic effects of nutritional ketosis: conceptual framework for keto-adaptation as a breast cancer therapy. Cancer Treat Res Commun 12:32–39. https://doi.org/10.1016/j.ctarc.2017.06.001
doi: 10.1016/j.ctarc.2017.06.001
Lussier DM, Woolf EC, Johnson JL et al (2016) Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet. BMC Cancer 16:10
doi: 10.1186/s12885-016-2337-7
Bandera-Merchan B, Boughanem H, Crujeiras AB et al (2020) Ketotherapy as an epigenetic modifier in cancer. Rev Endocr Metab Disord 21:509–519. https://doi.org/10.1007/s11154-020-09567-4
doi: 10.1007/s11154-020-09567-4 pubmed: 32514818
Klement RJ (2019) The influence of ketogenic therapy on the 5 R’s of radiobiology. Int J Radiat Biol 95:394–407. https://doi.org/10.1080/09553002.2017.1380330
doi: 10.1080/09553002.2017.1380330 pubmed: 28905672
Klement RJ, Pazienza V (2019) Impact of different types of diet on gut microbiota profiles and cancer prevention and treatment. Medicina (Kaunas) 55:E84. https://doi.org/10.3390/medicina5504008
doi: 10.3390/medicina5504008
Seyfried TN, Flores RE, Poff AM, D’Agostino DP (2014) Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis 35:515–527. https://doi.org/10.1093/carcin/bgt480
doi: 10.1093/carcin/bgt480 pubmed: 24343361
Klement RJ, Fink MK (2016) Dietary and pharmacological modification of the insulin/IGF-1 system: exploiting the full repertoire against cancer. Oncogenesis 5:e193. https://doi.org/10.1038/oncsis.2016.2
doi: 10.1038/oncsis.2016.2 pubmed: 26878387 pmcid: 5154349
Klement RJ, Brehm N, Sweeney RA (2020) Ketogenic diets in medical oncology: a systematic review with focus on clinical outcomes. Med Oncol 37:14. https://doi.org/10.1007/s12032-020-1337-2
doi: 10.1007/s12032-020-1337-2 pubmed: 31927631
Fearon KC, Borland W, Preston T et al (1988) Cancer cachexia: influence of systemic ketosis on substrate levels and nitrogen metabolism. Am J Clin Nutr 47:42–48
doi: 10.1093/ajcn/47.1.42
Ok JH, Lee H, Chung H-Y et al (2018) The potential use of a ketogenic diet in pancreatobiliary cancer patients after pancreatectomy. Anticancer Res 38:6519–6527. https://doi.org/10.21873/anticanres.13017
doi: 10.21873/anticanres.13017 pubmed: 30396981
Kämmerer U, Klement RJ, Joos FT et al (2021) Low carb and ketogenic diets increase quality of life, physical performance, body composition, and metabolic health of women with breast cancer. Nutrients 13:1029. https://doi.org/10.3390/nu13031029
doi: 10.3390/nu13031029 pubmed: 33806775 pmcid: 8004887
Burger K (2017) Ärzte warnen Krebspatienten vor Keto-Diäten. In: Süddeutsche Zeitung. https://www.sueddeutsche.de/gesundheit/medizin-aerzte-warnen-krebspatienten-vor-keto-diaeten-1.3687280
Klassen PN, Goldenberg BA, Lambert P et al (2020) Ketogenic and low-sugar diets for patients with cancer: perceptions and practices of medical oncologists in Canada. Support Care Cancer 28:5243–5249
doi: 10.1007/s00520-020-05361-9
Klement RJ, Feinman RD, Gross EC et al (2017) Need for new review of article on ketogenic dietary regimes for cancer patients. Med Oncol 34:108. https://doi.org/10.1007/s12032-017-0968-4
doi: 10.1007/s12032-017-0968-4 pubmed: 28452037
Klement RJ, Sweeney RA, Gross EC, Champ CE (2019) Problems associated with a highly artificial ketogenic diet: Letter to the Editor Re: van der Louw EJTM, Olieman JF, van den Bemt PMLA, et al. Ketogenic diet treatment as adjuvant to standard treatment of glioblastoma multiforme: a feasibility and safety. Ther Adv Med Oncol 11:1758835919879268. https://doi.org/10.1177/1758835919879268
doi: 10.1177/1758835919879268 pubmed: 31662797 pmcid: 6792271
Klement RJ (2019) The emerging role of ketogenic diets in cancer treatment. Curr Opin Clin Nutr Metab Care 22:129–134. https://doi.org/10.1097/MCO.0000000000000540
doi: 10.1097/MCO.0000000000000540 pubmed: 30531479
Klement RJ, Schäfer G, Sweeney RA (2020) A ketogenic diet exerts beneficial effects on body composition of cancer patients during radiotherapy: An interim analysis of the KETOCOMP study. J Tradit Complement Med 10:180–187. https://doi.org/10.1016/j.jtcme.2019.03.007
doi: 10.1016/j.jtcme.2019.03.007 pubmed: 32670812
Klement RJ, Champ CE, Kämmerer U et al (2020) Impact of a ketogenic diet intervention during radiotherapy on body composition: III—final results of the KETOCOMP study for breast cancer patients. Breast Cancer Res 22:94. https://doi.org/10.1186/s13058-020-01331-5
doi: 10.1186/s13058-020-01331-5 pubmed: 32819413 pmcid: 7441712
Klement RJ, Weigel MM, Sweeney RA (2021) A ketogenic diet consumed during radiotherapy improves several aspects of quality of life and metabolic health in women with breast cancer. Clin Nutr. https://doi.org/10.1016/j.clnu.2021.01.023
doi: 10.1016/j.clnu.2021.01.023 pubmed: 34233255
Klement RJ, Sweeney RA (2016) Impact of a ketogenic diet intervention during radiotherapy on body composition: II. Protocol of a randomised phase I study (KETOCOMP). Clin Nutr ESPEN 12:e1–e6. https://doi.org/10.1016/j.clnesp.2015.11.001
doi: 10.1016/j.clnesp.2015.11.001 pubmed: 28531663
Jenkins DG, Quintana-Ascencio PF (2020) A solution to minimum sample size for regressions. PLoS ONE 15:e0229345. https://doi.org/10.1371/journal.pone.0229345
doi: 10.1371/journal.pone.0229345 pubmed: 32084211 pmcid: 7034864
Klement RJ, Schäfer G, Sweeney RA (2019) A fatal case of Fournier’s gangrene during neoadjuvant radiotherapy for rectal cancer. Strahlenther Onkol 195:441–446. https://doi.org/10.1007/s00066-018-1401-4
doi: 10.1007/s00066-018-1401-4 pubmed: 30470845
Perini TA, de Oliveira GL, dos Santos OJ, Palha de Oliveira F (2005) Technical error of measurement in anthropometry. Rev Bras Med do Esporte 11:86–90. https://doi.org/10.1590/s1517-86922005000100009
doi: 10.1590/s1517-86922005000100009
Bosy-Westphal A, Schautz B, Later W et al (2013) What makes a BIA equation unique? Validity of eight-electrode multifrequency BIA to estimate body composition in a healthy adult population. Eur J Clin Nutr 67:S14–S21
doi: 10.1038/ejcn.2012.160
Bundesärztekammer (2019) Neufassung der Richtlinie der Bundesärztekammer zur Qualitätssicherung Richtlinie der Bundesärztekammer zur Qualitätssicherung laboratoriumsmedizinischer Untersuchungen. Dtsch Arztebl 116:A–2422. https://doi.org/10.3238/arztebl.2019.rili
Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F (2008) The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord 6:299–304. https://doi.org/10.1089/met.2008.0034
doi: 10.1089/met.2008.0034 pubmed: 19067533
Alizargar J, Hsieh N-C, Wu S-FV (2020) Is the use of triglyceride-glucose (TyG) index to recognize glucose disorders really practical? Eur J Pediatr 179:1169. https://doi.org/10.1007/s00431-020-03642-3
doi: 10.1007/s00431-020-03642-3 pubmed: 32415335
Kämmerer U, Schlatterer C, Knoll G (2012) Krebszellen lieben Zucker—Patienten brauchen Fett, 1st edn. Systemed
Zeevi D, Korem T, Zmora N et al (2015) Personalized nutrition by prediction of glycemic responses. Cell 163:1079–1095. https://doi.org/10.1016/j.cell.2015.11.001
doi: 10.1016/j.cell.2015.11.001 pubmed: 26590418
Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European organization for research and treatment of cancer QLC-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376
doi: 10.1093/jnci/85.5.365
Fayers P, Aaronson N, Bjordal K et al (2001) The EORTC QOL-C30 scoring manual (3rd Edition). European Organisation for Research and Treatment of Cancer, Brussels
Held L, Ott M (2018) On p -values and Bayes factors. Annu Rev Stat Its Appl 5:393–419
doi: 10.1146/annurev-statistics-031017-100307
Giesinger JM, Kieffer JM, Fayers PM et al (2016) Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust. J Clin Epidemiol 69:79–88. https://doi.org/10.1016/j.jclinepi.2015.08.007
doi: 10.1016/j.jclinepi.2015.08.007 pubmed: 26327487
Stafstrom CE, Rho JM (2012) The ketogenic diet as a treatment paradigm for diverse neurological disorders. Front Pharmacol 3:59. https://doi.org/10.3389/fphar.2012.00059
doi: 10.3389/fphar.2012.00059 pubmed: 22509165 pmcid: 3321471
Klement RJ, Koebrunner PS, Meyer D et al (2021) Impact of a ketogenic diet intervention during radiotherapy on body composition: IV. Final results of the KETOCOMP study for rectal cancer patients. Clin Nutr. https://doi.org/10.1016/j.clnu.2021.05.015
doi: 10.1016/j.clnu.2021.05.015 pubmed: 34233255
Masino SA, Ruskin DN (2013) Ketogenic diets and pain. J Child Neurol 28:993–1001. https://doi.org/10.1177/0883073813487595
doi: 10.1177/0883073813487595 pubmed: 23680946 pmcid: 4124736
Brenton JN, Banwell B, Bergqvist AGC et al (2019) Pilot study of a ketogenic diet in relapsing-remitting MS. Neurol—Neuroimmunol Neuroinflammation 6:e565. https://doi.org/10.1212/NXI.0000000000000565
doi: 10.1212/NXI.0000000000000565
Schreck KC, Lwin M, Strowd RE et al (2019) Effect of ketogenic diets on leukocyte counts in patients with epilepsy. Nutr Neurosci 22:522–527. https://doi.org/10.1080/1028415X.2017.1416740
doi: 10.1080/1028415X.2017.1416740 pubmed: 29254457
Sürmelıoğlu N, Paydaş S, Karataş Y, Seydaoğlu G (2017) Evaluation of lipid profiles in patients treated with capecitabine. Turkish J Med Sci 47:1206–1209. https://doi.org/10.3906/sag-1607-53
doi: 10.3906/sag-1607-53
Bar-Sela G, Haim N (2009) Uncontrolled hypertriglyceridemia induced by capecitabine: case report and review of the literature. Cancer Chemother Pharmacol 63:779–782. https://doi.org/10.1007/s00280-008-0799-2
doi: 10.1007/s00280-008-0799-2 pubmed: 18641989
Michie CO, Sakala M, Rivans I et al (2010) The frequency and severity of capecitabine-induced hypertriglyceridaemia in routine clinical practice: a prospective study. Br J Cancer 103:617–621. https://doi.org/10.1038/sj.bjc.6605807
doi: 10.1038/sj.bjc.6605807 pubmed: 20664584 pmcid: 2938254
Liu X, He G, Lo K et al (2021) The triglyceride-glucose index, an insulin resistance marker, was non-linear associated with all-cause and cardiovascular mortality in the general population. Front Cardiovasc Med 7:628109. https://doi.org/10.3389/fcvm.2020.628109
doi: 10.3389/fcvm.2020.628109 pubmed: 33521071 pmcid: 7840600
Okamura T, Hashimoto Y, Hamaguchi M et al (2020) Triglyceride-glucose index (TyG index) is a predictor of incident colorectal cancer: a population-based longitudinal study. BMC Endocr Disord 20:113. https://doi.org/10.1186/s12902-020-00581-w
doi: 10.1186/s12902-020-00581-w pubmed: 32709256 pmcid: 7379831
Fritz J, Bjørge T, Nagel G et al (2020) The triglyceride-glucose index as a measure of insulin resistance and risk of obesity-related cancers. Int J Epidemiol 49:193–204. https://doi.org/10.1093/ije/dyz053
doi: 10.1093/ije/dyz053 pubmed: 30945727
Lahm H, Suardet L, Laurent PL et al (1992) Growth regulation and co-stimulation of human colorectal cancer cell lines by insulin-like growth factor I, II and transforming growth factor α. Br J Cancer 65:341–346. https://doi.org/10.1038/bjc.1992.69
doi: 10.1038/bjc.1992.69 pubmed: 1558785 pmcid: 1977598
Palmqvist R, Hallmans G, Rinaldi S et al (2002) Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden. Gut 50:642–646. https://doi.org/10.1136/gut.50.5.642
doi: 10.1136/gut.50.5.642 pubmed: 11950809 pmcid: 1773192
Murphy N, Carreras-Torres R, Song M et al (2020) Circulating levels of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 associate with risk of colorectal cancer based on serologic and Mendelian randomization analyses. Gastroenterology 158:1300-1312.e20. https://doi.org/10.1053/j.gastro.2019.12.020
doi: 10.1053/j.gastro.2019.12.020 pubmed: 31884074
Khodabakhshi A, Akbari ME, Mirzaei HR et al (2020) Effects of ketogenic metabolic therapy on patients with breast cancer: a randomized controlled clinical trial. Clin Nutr 40:751–758. https://doi.org/10.1016/j.clnu.2020.06.028
doi: 10.1016/j.clnu.2020.06.028 pubmed: 32703721
Koutnik AP, Poff AM, Ward NP et al (2020) Ketone bodies attenuate wasting in models of atrophy. J Cachexia Sarcopenia Muscle 11:973–996. https://doi.org/10.1002/jcsm.12554
doi: 10.1002/jcsm.12554 pubmed: 32239651 pmcid: 7432582
Bandyopadhyay PS, Brittan G Jr, Taper ML (2016) Belief, evidence, and uncertainty: problems of epistemic inference, 1st edn. Springer International Publishing, Basel
doi: 10.1007/978-3-319-27772-1

Auteurs

Rainer J Klement (RJ)

Department of Radiation Oncology, Leopoldina Hospital Schweinfurt, Robert-Koch-Straße 10, 97422, Schweinfurt, Germany. rainer_klement@gmx.de.

Detlef Meyer (D)

Darmzentrum Leopoldina Hospital, Schweinfurt, Germany.

Stefan Kanzler (S)

Darmzentrum Leopoldina Hospital, Schweinfurt, Germany.

Reinhart A Sweeney (RA)

Department of Radiation Oncology, Leopoldina Hospital Schweinfurt, Robert-Koch-Straße 10, 97422, Schweinfurt, Germany.
Darmzentrum Leopoldina Hospital, Schweinfurt, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH